Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,529.81
    +1,241.30 (+1.42%)
     

  • CMC Crypto 200

    1,334.09
    +21.47 (+1.64%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON TECH DRAG

Nvidia tumbles 10%, Amazon loses more than 2% while Apple ends 1% lower

CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Deadlines to File Lead Plaintiff Motions Related to the Following Companies: VAL, MYGN, COF

ACCESSWIRE

BALA CYNWYD, PA / ACCESSWIRE / October 19, 2019 / Brodsky & Smith, LLC reminds investors of important deadlines for lead plaintiff application regarding class action lawsuits against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.

VALARIS plc (VAL)

Shares purchased between April 11, 2019 and July 31, 2019

Deadline: October 21, 2019

ADVERTISEMENT

According to the filed complaint, on July 31, 2019, Valaris issued a press release announcing its second quarter 2019 financial results-which missed market expectations. Upon issuance of the press release, analysts at Seeking Alpha published an article on August 2, 2019, entitled "Valaris PLC - Off To A Bad Start." and noted that Valaris' results "shock[ed] investors with massive cash usage [and] . . . surprisingly weak outlook for the ultra-deepwater segment with further dayrate recovery likely delayed until at least the second half of next year." The article further criticized Valaris' free cash flow for the quarter, which was "negative by a whopping $375 million causing the company's remaining pro forma cash balance adjusted for roughly $741 million in payments related to the recent debt tender offer to decline to just $353 million." Following this news, Valaris' stock price fell $3.25 per share, or approximately 39%, over the two trading sessions following its announcement of its quarterly financial results, to close at $5.02 per share on August 2, 2019.

Additional information can be found at http://www.brodskysmith.com/cases/valaris-plc-nyse-val/ or call 877-534-2590. No cost or obligation to you.

MYRIAD GENETICS, INC. (MYGN)

Shares purchased between September 2, 2019 and August 13, 2019

Deadline: November 26, 2019

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the FDA had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused Myriad to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on Myriad's revenue; and (v) as a result, Myriad's public statements were materially false and misleading at all relevant times.

Additional information can be found at http://www.brodskysmith.com/cases/myriad-genetics-inc-nasdaq-mygn/, or call: 877-534-2590. No cost or obligation.

CAPITAL ONE FINANCIAL CORPORATION (COF)

Shares purchased between February 2, 2018 and July 29, 2019

Deadline: December 2, 2019

On July 29, 2019, Capital One announced in a press release that it had suffered a data breach affecting over 106 million individuals in the United States and Canada. On this news, shares of Capital One fell $5.71 or nearly 5.9% to close at $91.21 on July 30 2019.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company did not maintain robust information security protections, and its protection did not shield personal information against security breaches; (2) such deficiencies heightened the Company's exposure to a cyber-attack; and (3) as a result, Capital One's public statements were materially false and misleading at all relevant times.

Additional information can be found at http://www.brodskysmith.com/cases/capital-one-financial-corporation-nyse-cof/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/563233/CLASS-ACTION-DEADLINES-Brodsky-Smith-LLC-Reminds-Investors-of-Deadlines-to-File-Lead-Plaintiff-Motions-Related-to-the-Following-Companies-VAL-MYGN-COF